Robert Eustace – Trademark Portfolio
Entity Type: 01
Robert Eustace holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 1 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 4 Nice Classification classes. Currently, 1 trademark is registered and 1 is pending. Notable registered marks include THE LAMINITIS CLINIC. The owner is based in Boston, MA.
105 Salem St
Boston, MA 02113
Showing of trademarks Trademarks
Trademark Classifications
Robert Eustace's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Paper and cardboard; printed matter; bookbinding material; photographs; stationery
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Robert Eustace have?
Robert Eustace has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 pending.
What trademark classes does Robert Eustace file in?
Robert Eustace files trademarks across 4 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 44 (Medical Services), Class 16 (Paper Goods), Class 5 (Pharmaceuticals). Class 35 covers advertising; business management; business administration; office functions.
What are Robert Eustace's most well-known trademarks?
Robert Eustace's registered trademark portfolio includes well-known marks such as THE LAMINITIS CLINIC. These are among 1 currently registered trademark in the portfolio.
What is Robert Eustace's trademark registration success rate?
Robert Eustace has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 1 application is pending review.